Holland & Knight Health Briefing January 27 2026 Key Insights
Holland & Knight delivers this Health Briefing for January 27, 2026, tracking the fast-moving intersection of Medical Policy, Health Regulations and market behavior. The thread running through this update is simple: when federal funding, payment models and data rules shift at the same time, operational risk rises—yet so does the opportunity for smarter care.
To make the policy impact feel real, consider a composite scenario: a multi-state health system, a regional Medicare Advantage plan and a digital pharmacy platform all trying to finalize Q1 priorities while Washington’s calendar and weather both disrupt timelines. The question to keep asking is: what changes tomorrow’s decisions in clinics, plans and supply rooms today?
Healthcare Insights: Federal Funding Uncertainty and Public Health Stakes
Negotiations around a multi-bill appropriations package have become less predictable after a weekend incident in Minneapolis intensified calls from Senate Democrats to separate DHS funding from the broader package. Several senators signaled “no” votes unless that funding is carved out and paired with stronger limits on certain DHS and ICE activities.
Senate leadership on the Republican side has indicated an intention to advance the package as passed by the House, without removing DHS-related provisions—an approach that can require procedural steps needing near-unanimous support. With the House out of session and not scheduled to return until early February (after the funding deadline), and winter storms disrupting travel and schedules, the path that once looked straightforward now looks fragile. The practical insight: when legislative timing slips, downstream Public Health programs and vendor contracts often pause too.
For additional context on how system shocks reverberate across providers and payers, this overview of shifting care dynamics is a useful companion read: how COVID-19 continues to reshape the healthcare landscape. The enduring takeaway is that policy turbulence tends to accelerate already-emerging operational shifts.
Upcoming hearings and meetings that can move Medical Policy
Several near-term events deserve attention because they can rapidly convert into oversight pressure, new guidance or legislative text. These are the kinds of calendar items that compliance teams track the way nutrition-focused readers track ingredient labels—small details, big consequences.
- Jan. 28: Senate Veterans’ Affairs hearing on restructuring efforts inside the Veterans Health Administration, framed as building a “21st century” VA health care system.
- Jan. 29: Senate Aging hearing focused on drug origin transparency, putting supply chain integrity and labeling scrutiny in the spotlight.
- Jan. 29-30: MACPAC monthly meeting covering Medicaid payment policy for the HCBS workforce, managed care accountability options, residential access for youth behavioral health, community engagement requirements, transitions for special health needs, Medicaid/CHIP behavioral health, justice-involved youth reentry, automation in prior authorization, PACE oversight and HCBS self-direction.
- Feb. 11-12: ASTP/ONC annual meeting highlighting transparency and affordability, tech-enabled care, data liquidity and AI adoption in clinical practice.
- Feb. 19: HITAC resumes after a year-long pause, returning amid leadership turnover at the co-chair level.
The common thread is accountability—who pays, who proves value and who controls the data. That accountability focus sets up the payment and regulation changes arriving next.
Health Regulations: CMS Signals Medicare Advantage and Part D Shifts
CMS released the CY 2027 Advance Notice with proposals that aim to tighten payment accuracy while modernizing measurement. Even for readers who follow nutrition science more than actuarial tables, the logic is familiar: better inputs produce more reliable outputs.
On Medicare Advantage, CMS proposes a refreshed HCC risk adjustment approach calibrated with more recent diagnosis and cost patterns, while keeping much of the current structure intact. It also proposes to exclude certain diagnosis sources—notably audio-only services where face-to-face standards apply—and to limit risk score contributions from chart review records that are not linked to encounters or fee-for-service claims. The operational implication for plans and provider groups is clear: documentation workflows and coding governance may need to be rebuilt around encounter-linked evidence.
On Part D, CMS proposes risk adjustment updates aligned to Inflation Reduction Act benefit changes and more current cost data, with a sharper separation of cost patterns between MA-PD and standalone PDP products. CMS also proposes updates to Star Ratings timelines and measurement specifications, plus stronger use of reporting data to validate appeal timeliness with scaled penalties when data quality fails. Comments are due by Feb. 25, and the final rate announcement is expected on or before Apr. 6, which creates a tight planning runway.
Quick-reference table: what changes and who feels it first
| Policy move | What it changes | First-order impact | Example operational response |
|---|---|---|---|
| 2027 HCC recalibration | Updates how diagnoses translate into MA payments using newer data years | Revenue and benchmark shifts; renewed scrutiny of coding patterns | Align clinical documentation improvement with encounter-based evidence |
| Excluding audio-only diagnoses | Limits certain remote diagnosis submissions for risk scoring | Telehealth workflow redesign; member access vs. compliance tradeoffs | Route complex assessments to compliant modalities and document necessity |
| Chart review linkage requirement | Reduces risk score use of unlinked chart review records | Vendor models and retrospective review strategies may change | Require encounter/claims linkage in audit trails and contracts |
| Part D risk adjustment updates | Reflects IRA benefit design and cost trends | Bid strategy changes; PBM contracting pressure | Refresh forecasting assumptions and renegotiate rebate/admin terms |
| Star Ratings refinements | New deadlines, measure edits and stronger data validation | Higher penalty risk for weak reporting and appeals timeliness | Automate evidence capture and run pre-submission data quality checks |
This kind of technical change often feels distant—until it hits benefits design, prior authorization friction or network decisions. That’s where Healthcare Innovation and analytics become less of a buzzword and more of a survival tool.
Tracking Star Ratings and risk adjustment can also help decode why plans change formularies, care management outreach and member communications. Those signals often arrive earlier than formal notices in the mail.
Healthcare Innovation: AI Concentration, Data Liquidity and Clinical Reality
A Council of Economic Advisers report on AI and economic divergence frames artificial intelligence as a general-purpose technology already showing measurable effects on productivity. The report emphasizes how concentrated AI computing capacity and investment have become, with the U.S. holding a dominant share of compute, and with model capability rising faster than many historical technology transitions.
Even though the report isn’t written specifically for health systems, its implications land squarely in research-heavy and data-dependent sectors. The organizations that win are those that combine compute access with integration into workflows, plus investments in talent and process redesign. A small hospital group might have great clinicians, yet still fall behind if it cannot operationalize AI safely across scheduling, imaging triage or utilization management.
One counterintuitive lesson from industrial history also appears here: efficiency can increase total usage (often discussed as Jevons’ Paradox). In healthcare, that can translate to faster interpretation leading to more imaging, or easier triage leading to more visits. The insight is that better tools still require demand management and ethical guardrails.
What to watch at the ASTP/ONC annual meeting
The ASTP/ONC annual meeting agenda highlights transparency and affordability, the future of tech-enabled care, data liquidity and ways to accelerate AI integration into clinical practice. For a compliance-minded operator, the curious question is: how quickly will interoperability expectations become de facto requirements in payer-provider contracts?
For a broader view of innovation momentum across global health and medtech, this overview provides helpful perspective: global health breakthroughs shaping modern care. The key is translating breakthroughs into governed, equitable workflows.
When data moves more freely, accountability rises as well—especially for prior authorization automation, appeals timeliness and clinical decision support.
Health Law and Oversight: Enforcement, PBMs and Transparency Pressure
Several federal updates point to a governance-heavy season for Health Law. HHS has tapped former federal prosecutor Scott Brady to lead department-wide anti-fraud efforts, reinforcing the message that program integrity remains a top-tier priority.
On Capitol Hill, leaders of the Senate HELP Committee sent a letter supporting continued improvements to No Surprises Act implementation, with attention to the Independent Dispute Resolution process and the resources needed to keep disputes moving. In parallel, the House Judiciary Committee released an interim staff report on PBMs and competitive dynamics, emphasizing “hub pharmacy” technology and raising questions about whether current legal frameworks adequately address emerging pharmacy models.
At the same time, House Energy and Commerce Democratic leaders asked HHS for details on terminated grant funding connected to a national pediatrician group, requesting answers to a set of questions by early February. The policy signal is that children’s health funding decisions will face intensified oversight, and organizations touched by federal grants should be ready to explain program outcomes with evidence, not slogans.
Executive actions and workforce litigation: why governance teams are busy
Wide-ranging executive orders continue to influence agency priorities and interpretations. In addition, a federal judge approved a path for dismissed HHS employees to pursue class action status, with claims that reductions in force relied on faulty information such as veteran status and performance ratings. If the case proceeds as a broad class, it could shape how future workforce actions are documented and challenged.
Even readers focused on wellness habits can recognize the parallel: systems run best when inputs are accurate. In law, “clean data” is the difference between defensible decisions and prolonged disputes.
Food, Nutrition and Device Updates: FDA and NIH Developments to Track
Regulatory attention is also intensifying around the daily health choices that happen in kitchens, pharmacies and living rooms. The FDA released a set of priority deliverables for the Human Foods Program, spanning food chemical safety, microbiological safety and nutrition initiatives tied to chronic disease reduction.
Notable items include work toward front-of-package nutrition labeling, modernization of recall processes, a proposed reform to the GRAS notification program and progress on guidance for new dietary ingredients. In a separate action, FDA opened a request for information on gluten disclosure in packaged foods, prompted by a citizen petition seeking clearer ingredient naming and stronger cross-contact controls—especially relevant for consumers managing celiac disease.
In cosmetics oversight, FDA issued guidance clarifying when it can access records under MoCRA if a product or ingredient is suspected of presenting serious health risk. For companies, the lesson is to treat recordkeeping as a core safety control, not an afterthought.
On devices, FDA issued draft recommendations for clinical performance testing for cuffless blood pressure measurement tools. This matters because consumer-grade convenience is racing ahead, and regulators are signaling that validation across age ranges and special populations cannot be optional.
NIH also announced the reestablishment of a sickle cell advisory committee to support research planning and priorities. Separately, NIH reinstated a policy ending the use of NIH funds for research involving human fetal tissue and issued an RFI on reducing reliance on human embryonic stem cells, inviting comment through late April. These moves can reshape research roadmaps, vendor partnerships and institutional review processes.
Payment model signals: PTAC dates for 2026
HHS published the schedule for Physician-Focused Payment Model Technical Advisory Committee meetings, held both virtually and in person. Dates include Feb. 23-24, June 15-16, Sept. 14-15 and Dec. 8-9. For organizations designing alternative payment models, these dates are checkpoints for aligning proposals with evolving Medicare priorities.
For a wider lens on medical growth trends and why policy timing can matter for adoption curves, this recap is helpful: medical growth themes highlighted around CMEF 2025. The throughline into 2026 is that innovation spreads fastest when payment and evidence standards are aligned.
How could the appropriations package uncertainty affect healthcare operations?
When federal funding timelines slip, agencies and grantees often delay awards, guidance and contracting. That can cascade into paused pilots, slower hiring for public health programs and cautious vendor spend until budget certainty returns.
What is the practical takeaway from CMS proposing to limit certain diagnosis sources for risk adjustment?
Plans and provider groups may need tighter documentation and encounter-linking controls so that diagnoses used for payment are supported by compliant service records. This can change vendor chart review strategies and reshape telehealth workflows.
Why does AI concentration matter for healthcare innovation?
If compute capacity and advanced models remain concentrated, larger systems may adopt AI faster and capture more productivity gains. Smaller organizations can narrow the gap by focusing on governed use cases, interoperability and workforce upskilling rather than chasing every tool.
What do FDA’s food priorities suggest for nutrition and chronic disease prevention?
Expect more regulatory attention on clearer labeling, chemical safety and modernized recall processes. For consumers and clinicians, better front-of-package labeling and clearer ingredient disclosure can support healthier choices and improved risk management for allergies or celiac disease.
Which near-term meetings are most relevant for Medicaid policy watchers?
The MACPAC meeting at the end of January is a key marker, with agenda items spanning HCBS workforce payment policy, managed care accountability, behavioral health access for youth, prior authorization automation and PACE oversight—topics that frequently influence state program directions.